The 4th Mitochondrial Dysfunction Drug Development Summit was the only meeting dedicated to advancing the therapeutic development of mitochondria targeting drugs, through connecting pathogenesis discoveries made in academia with drug development case studies to enable expedited discovery, preclinical and clinical strategy with translatable relevance across indications with a mitochondrial dysfunction driver. Our experts across both primary and secondary mitochondrial diseases still need your help to identify biomarkers and develop therapeutic strategies that involve targeting mitochondrial pathogenic mechanisms.